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Copenhagen, Copenhagen, DenmarkPeptide nucleic acids (PNAs) are potentially attractive anti-
sense agents against hepatitis B virus (HBV), although poor
cellular uptake limits their therapeutic application. In the
duck HBV (DHBV) model, we evaluated different cell-pene-
trating peptides (CPPs) for delivery to hepatocytes of a
PNA-targeting hepadnaviral encapsidation signal (ε). This
anti-ε PNA exhibited sequence-speciﬁc inhibition of DHBV
RT in a cell-free system. Investigation of the best in vivo
route of delivery of PNA conjugated to (D-Arg)8 (P1) showed
that intraperitoneal injection to ducklings was ineffective,
whereas intravenously (i.v.) injected ﬂuorescein-P1-PNA
reached the hepatocytes. Treatment of virus carriers with
i.v.-administered P1-PNA resulted in a decrease in viral
DNA compared to untreated controls. Surprisingly, a similar
inhibition of viral replication was observed in vivo as well as
in vitro in primary hepatocyte cultures for a control 2 nt mis-
matched PNA conjugated to P1. By contrast, the same PNA
coupled to (D-Lys)4 (P2) inhibited DHBV replication in a
sequence-speciﬁc manner. Interestingly, only P1, but not
P2, displayed anti-DHBV activity in the absence of PNA
cargo. Hence, we provide new evidence that CPP-PNA conju-
gates inhibit DHBV replication following low-dose adminis-
tration. Importantly, our results demonstrate the key role of
CPPs used as vehicles in antiviral speciﬁcity of CPP-PNA con-
jugates.Received 1 August 2017; accepted 7 September 2017;
https://doi.org/10.1016/j.omtn.2017.09.003.
Correspondence: Lucyna Cova, INSERM U1052, Cancer Research Center of Lyon
(CRCL), University of Lyon, 151 cours A. Thomas, 69003 Lyon, France.
E-mail: lucyna.cova@inserm.frINTRODUCTION
Hepatitis B virus (HBV) remains the major cause of chronic hepatitis,
still accounting for at least 600,000 deaths per year worldwide.1
Currently, pegylated interferon-a and nucleos(t)ide analogs
(NUCs) are the only drugs approved for the treatment of chronic
HBV infection.2,3 However, these NUCs targeting viral polymerase
only have a virostatic effect because rebound of viral replication is
common after therapy cessation.4 The global prevalence of HBV
infection together with the lack of effective treatment warrants the
search for novel therapeutic options as a functional cure for chronic
hepatitis B.162 Molecular Therapy: Nucleic Acids Vol. 9 December 2017 ª 2017 T
This is an open access article under the CC BY-NC-ND license (httpIn this context, peptide nucleic acids (PNAs) represent promising
candidates as inhibitors of HBV replication. PNAs are synthetic
DNA mimics having a pseudopeptide backbone that are able to
bind with high afﬁnity to complementary DNA or RNA. Further-
more, their remarkable stability against enzymatic degradation in bio-
logical ﬂuids makes them potentially attractive antiviral com-
pounds.5–9 PNAs are currently considered as “third generation”
antisense and anti-gene agents. Importantly, PNAs can be designed
to target other stages of HBV replication than viral polymerase,
thus limiting the selection of drug-resistant mutants. However,
limiting cellular uptake, owing to the fact that they are large hydro-
philic molecules, has challenged the broad application of unmodiﬁed
PNA as antiviral agents.
In the past decade, a series of natural and synthetic cell-penetrating
peptides (CPPs) have been discovered and applied as membrane-
permeable delivery vehicles for a wide range of cargo, including
PNAs.10–12 CPPs typically contain clusters of arginine or lysine resi-
dues sharing a small size, less than 30-aa residues, and cationic charge.
Different studies revealed the potential of CPPs as promising nonviral
gene carriers being used as “Trojan horses” to introduce therapeuti-
cally relevant cargo into cells. Indeed, oligoarginines are internalized
by mammalian cells, and their ability to increase cellular uptake and
antisense activity of CPP-PNA conjugates has been convincingly
demonstrated in several studies.13–15 The tetralysine tail was previ-
ously found to be important for the antisense activity of PNAs in cells
and in vivo in a mouse model.16,17 Additionally, the HIV-1-derived
TAT peptide was recently shown to enhance intracellular distribution
and antisense activity of a PNA oligomer targeting a direct repeat
sequence of HBV following hydrodynamic injection of viral genomes
intomice.18 However, studies on the therapeutic efﬁcacy of CPP-PNAhe Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Uptake of CPP-PNA Conjugates following Different Routes of
In Vivo Delivery
Representative fluorescence microscopy images of liver sections 48 hr after i.v or
i.p. injection of fluorescein-PNA coupled to P1 (D-Arg)8. (A–C) Fluorescent staining
of livers from control uninjected duckling (hepatocyte autofluorescence) (A) or
ducklings injected with fluorescein-P1-PNA via i.p. route (B) or via i.v. route (C).
Figure 2. Effect of P1-PNA Conjugates on Viral Replication In Vivo
DHBV-infected ducklings received an i.v. injection of CPP-PNA conjugates daily
during 6 consecutive days. (A) Serum DHBV DNA was monitored by dot-blot hy-
bridization over a 6-day time course of treatment. The mean DHBV DNA titers in
vge/mL for each group of ducks quantified by PhosphorImager scanning is repre-
sented. (B) Viral DNA was analyzed in liver samples at the end of a 6-day treatment
with P1-PNA or P1-MM PNA. PhosphorImager quantifications of all DHBV DNA
replicative forms from Southern blot analysis of intrahepatic DNA are represented
and expressed as a percentage of inhibition, considering untreated controls as
100%. Percentages of inhibition are indicated.
www.moleculartherapy.orgconjugates have so far exclusively been conducted in mouse models,
and the ability of these conjugates to inhibit the full replication cycle
of hepadnaviruses in vitro and in vivo has not yet been investigated.
In the present study, we explored the ability of an antisense PNA tar-
geting the duck HBV (DHBV) ε coupled to different CPPs to inhibit
hepadnaviral replication. The DHBV model, a reference for evalua-
tion of novel anti-HBV approaches, provides a unique opportunity
to study the antiviral potential of CPP-PNA conjugates in vitro in pri-
mary duck hepatocyte culture (PDH) as well as in vivo in Pekin duck-
lings.19 Having previously demonstrated the ability of this PNA-tar-
geting hepadnaviral encapsidation signal ε to inhibit viral RT in a
sequence-speciﬁc manner in a rabbit reticulocyte extract,20 we conju-
gated this PNA to CPPs to increase hepatocyte penetration in a
DHBV context because the major challenge of therapeutic PNA
application is their inefﬁcient cell uptake.14
We ﬁrst deﬁned the most effective in vivo route of delivery using a
ﬂuorescein-labeled CPP-PNA conjugate administrated to uninfected
animals. On the basis of our previous results, we selected (D-Arg)8 as
CPP for PNA coupling, which exhibited a weaker inhibitory activity
on DHBV egress compared to Decanoyl(Arg)8.
21 Next, we compared
the ability of different CPP-PNA conjugates to inhibit DHBV repli-
cation in vitro and in vivo. We report herein that intravenously (i.v.)
injected (D-Arg)8-PNA, in contrast to the intraperitoneal (i.p.) route
of delivery, reached the liver and inhibited DHBV replication.
Notably, our study also revealed that the choice of CPP as a vehicle
for cellular delivery of its PNA cargo plays a crucial role in the spec-
iﬁcity of hepadnaviral replication inhibition by CPP-PNA
conjugates.
RESULTS
Optimization of CPP-PNA Conjugate Delivery Route In Vivo
To optimize the conditions for PNA in vivo administration to duck-
lings, the i.v. and i.p. PNA delivery route were investigated. The ﬂuo-
rescein-PNA coupled to P1 CPP was i.v. or i.p. injected into DHBV-
free ducklings, and the hepatocyte-associated ﬂuorescence was
analyzed by ﬂuorescence microscopy 48 hr later. As illustrated in Fig-
ure 1, little or no cell-associated ﬂuorescence was detected after i.p.
injection of ﬂuorescein-P1-PNA (Figure 1B). By contrast, the ﬂuores-cein-PNA coupled to P1 CPP was efﬁciently delivered to the liver
following i.v. injection (Figure 1C). This indicates that the injection
via i.v. route of ﬂuorescein isothiocyanate (FITC)-PNAs coupled to
a cationic CPP led to a better liver delivery than the i.p. route. Fluo-
rescence was predominantly detected in the hepatocytes and to some
extent also in the kidney and spleen but not in the lungs.
Inhibition of DHBV Replication In Vivo by P1-PNA Conjugates
and P1 Alone
DHBV-infected ducklings were randomly assigned into different
treatment groups that received antisense PNA, as described in the
therapeutic protocol. Viremia was followed daily in ducklings from
all groups. The follow up of serumDHBVDNA titers in the untreated
controls showed the typical evolution of viremia in the DHBV-in-
fected ducklings, reaching a peak value at day 5 post-inoculation
(p.i.), followed by a decrease starting from day 5 p.i. (Figure 2A).
The administration of P1-PNA conjugates (1 mg/g/body weight
[bw]/day) led to delayed and reduced viremia in treated ducklings,
as measured by the decrease in the total virus release during the treat-
ment, compared with the untreated controls. However, unexpectedly,
the administration of a control mismatched PNA differing by only
2 nt and coupled to the same CPP (P1-MM-PNA conjugate) alsoMolecular Therapy: Nucleic Acids Vol. 9 December 2017 163
Figure 3. Effect of P1 Alone on Viremia
Serum DHBV DNA was analyzed by dot-blot hybridization during a 6-day time
course of P1 (D-Arg)8 administration at 1 or 2 mg/gbw/day to virus-infected duck-
lings. The mean DHBV DNA titers in vge/mL for each group of ducks are repre-
sented.
Molecular Therapy: Nucleic Acidsinduced a decrease and delay in viremia in treated animals
(Figure 2A).
Next, we analyzed the impact of treatment on intrahepatic viral repli-
cation. As illustrated in Figure 2B, the analysis of liver DNA showed
that treatment with P1-PNA conjugates and its corresponding P1-
MM PNA decreased viral DNA synthesis by 51% and 66%, respec-
tively, compared to controls. Because the treatment with the 2 nt mis-
matched PNA sequence also led to a decrease in serum and liver
DHBV DNA, we asked whether the observed inhibition of viral repli-
cation was due to an antiviral effect of P1 CPP alone. To this end, a
similar experiment was performed as described above but using P1
alone. Brieﬂy, DHBV-infected ducklings were i.v. treated with 1 or
2 mg/gbw/day of P1 for 6 days. Interestingly, the injection of 1 or
2 mg/gbw/day of P1 induced a decrease, in a dose-dependent manner,
of viremia in treated animals compared with the untreated controls
(Figure 3). No loss of weight was noticed within the different treat-
ment groups compared with the untreated controls during the
follow-up period (data not shown), indicating the absence of in vivo
toxicity of P1-PNA conjugates or P1 CPP alone.
Altogether, these data implied that treatment of DHBV-infected
ducklings by an anti-ε P1-PNA conjugate or its 2 nt MM PNA
coupled to the same P1 CPP decreased DHBV replication in vivo.
Because the P1 alone inhibited DHBV replication in vivo, this may
explain the limited sequence speciﬁcity of P1-PNA conjugates.
In Vitro Effect of P1-PNA Conjugates or P1 CPP on DHBV
Replication
To further investigate the inhibitory effect of P1-PNA conjugates or
P1 alone, we have evaluated their antiviral efﬁcacy in vitro in
DHBV-infected primary hepatocyte cultures. The analysis of PDHs
treated with P1-PNA conjugates or P1-MM PNA showed a similar
decrease in the release of viral particles into cell culture supernatants,
which was estimated to be 47% and 52% of inhibition, respectively,
compared with untreated controls (Figures 4A and 4B). In addition,164 Molecular Therapy: Nucleic Acids Vol. 9 December 2017these results were conﬁrmed by a decrease in all intracellular viral
DNA replicative intermediates by about 59% and 60%, respectively,
in P1-PNA conjugates or P1-MM PNA-treated cells (Figure 4C).
Moreover, treatment of PDH by P1 alone also led to a decrease in
DHBV DNA levels in both supernatants and cells by 37% and 44%,
respectively, compared with the untreated controls (Figures
4A–4C). The observed antiviral effect was not related to any general
cytotoxicity of the peptide or peptide-PNA conjugates because P1-
PNA, P1-MM PNA conjugates, or P1 itself did not display signiﬁcant
toxicity in PDH cultures, as assessed by Neutral Red uptake test
(Figure S1).
Thus, the in vitro study corroborated the inhibitory effect of P1-PNA
and P1-MM PNA conjugates on DHBV replication observed in vivo.
The cationic CPP (D-Arg)8 alone, in the absence of its PNA cargo, ex-
hibited anti-DHBV activity both in vitro in PDH and in vivo in duck-
lings, thereby suggesting that this antiviral effect may affect the anti-
viral speciﬁcity of CPP-PNA conjugates.
Antiviral Effect of CPP-PNA Conjugates Depends of CPPs Used
as a Vehicle
To further explore the role of CPP used as a vehicle for PNA-medi-
ated inhibition of DHBV replication in PDH, we analyzed the anti-
viral effect of the same anti-ε PNA, but coupled to another cationic
CPP (D-Lys)4 termed P2. In addition, the antiviral effect of this
CPP alone was investigated. By using the same experimental
approach as described above, the ability of this CPP and CPP-PNA
conjugates to inhibit DHBV replication was analyzed in PDH cul-
tures. As illustrated in Figure 5, treatment with P2-PNA conjugates
led to the inhibition by about 48% of DHBV release in cell culture su-
pernatants. In addition, Southern blot analysis showed a similar 48%
decrease of intracellular DHBVDNA. Importantly, the inhibition was
speciﬁc because a 2-base mismatch PNA conjugated to the same
P2 CPP showed no marked inhibitory effect on released DHBV and
on intracellular viral replication (Figures 5A–5C). Moreover, treat-
ment with P2 alone resulted in neither the marked decrease of
DHBV in cell culture supernatants nor the intracellular DHBV
DNA content (Figure 5 and data not shown). These results, reproduc-
ibly observed in two independent experiments, are consistent with the
conclusion that the antiviral effects of the CPP as such is responsible
for the reduced sequence-speciﬁc activity of CPP-PNA conjugates. In
contrast, in the absence of such inhibitory CPP action, the CPP-PNA
conjugates are able to speciﬁcally inhibit DHBV replication.
Neither the (D-Lys)4-PNA conjugate nor (D-Lys)4 alone exhibited
toxicity in PDH cultures, as assessed by Neutral Red uptake test
(data not shown).
DISCUSSION
Understanding structure-activity relations is crucial for the develop-
ment of CPP-PNA conjugates as antiviral agents. In this preclinical
study, we explored the ability of CPP-PNA conjugates targeting the
hepadnaviral encapsidation signal ε to inhibit viral replication
in vitro and in vivo. Because the human HBV has an extremely
Figure 4. Analysis of Viral Replication In Vitro in PDH Cultures following Treatment with P1-PNA Conjugates or P1 Alone
Primary duck hepatocyte cultures were plated and infected with DHBV, followed by treatment with P1-PNA, P1-MMPNA, or P1 alone. (A) The viral release in supernatants of
DHBV-infected PDHs was monitored between days 3 and 6 post-infection by dot-blot hybridization and quantified by PhosphorImager. (B) Relative areas under curve of viral
release determined by the means of duplicate and compared to untreated cells (set as 100%) are represented. (C) PhosphorImager quantifications of DHBV DNA replicative
forms from Southern blot analysis of intracellular DNA. The mean relative band intensity for each group was normalized against untreated control cells (set as 100%) and SDs
are shown. Percentages of inhibition are indicated.
www.moleculartherapy.orgnarrow host range, we used DHBV-infected PDH culture and Pekin
ducks as model systems. The DHBV represents a reference model
validated by us and others for the evaluation of novel anti-HBV ap-
proaches in preclinical studies.19–27
Using this in vivo model, our team has previously demonstrated that
i.v. delivery of antisense phosphodiester oligodeoxynucleotides
(ODNs) complexed to polyethylenimine can selectively block hepad-
naviral replication in the liver.23 Among various antisense ap-
proaches, PNAs are currently being considered as particularly prom-ising third-generation antisense agents due to their unique structural
features, high sequence selectivity, and very high biostability.5,9 These
ﬁndings provide a rationale for the development of an innovative,
PNA-based approach for chronic hepatitis B treatment. We have
initially shown that antisense PNA targeting the DHBV ε exhibits a
potent, highly sequence-speciﬁc inhibitory effect on the DHBV RT
in a cell-free transcription and translation system.20
Because one of the major limitations regarding therapeutic use of
PNAs is poor transport across the cell membrane, we focused hereinMolecular Therapy: Nucleic Acids Vol. 9 December 2017 165
Figure 5. Effect of Treatment with P2-PNA Conjugates or P2 Alone on Viral Replication In Vitro in PDH Cultures
PDH cultures were plated, infected with DHBV, and treated with P2(D-Lys)4-PNA, P2-MM PNA, or P2 alone. (A) Cell supernatants were collected and DHBV DNA was
quantified between days 3 and 6 post-infection by dot-blot hybridization and quantified by PhosphorImager scanning. (B) Relative areas under the curve of viral release
determined by the means of duplicate and compared to untreated cells (set as 100%) are shown. (C) Quantifications by PhosphorImager of DHBV DNA replicative forms from
Southern blot analysis of intracellular DNA. The mean relative band intensity relative to untreated controls (set as 100%) and SDs are represented. Percentages of inhibition
are represented.
Molecular Therapy: Nucleic Acidson the intracellular delivery of anti-ε PNA coupled to CPPs such as
oligoarginine or oligolylysine. Indeed, it has been reported that oli-
goarginine conjugation greatly enhances the cellular delivery and
antisense activity of PNA.15,28–30 In addition, PNAs bearing oligoly-
sine tails exhibit enhanced cellular uptake, without compromising
sequence selectivity.16,17,31,32 However, in spite of numerous studies
aiming at elucidating the mechanisms of CPP-PNA conjugate entry
and uptake in cultured cells, data on in vivo activity of such conjugates
are scarce and essentially limited to mouse models.18,33,34
In the present study, we initially examined the ability of PNA target-
ing theDHBV encapsidation signal ε to inhibit viral replication in vivo166 Molecular Therapy: Nucleic Acids Vol. 9 December 2017by comparing the uptake of ﬂuorescein-labeled PNA coupled to P1
(D-Arg)8 following i.p. or i.v. administration. Unlike the mouse
model, in which an i.p. injection led to an effective PNA delivery,34
we demonstrate here that this route of delivery was inefﬁcient in
the duck model. Indeed, hepatocyte-associated ﬂuorescence was
only observed following i.v. injection of ﬂuorescein-P1-PNA into
ducklings. Collectively, these results suggest that the pharmacoki-
netics of PNA may differ according to the mode of injection and an-
imal model used.
Importantly, using a low CPP-PNA conjugate dose (1 mg/gbw/day),
we found efﬁcient liver uptake of such conjugates associated with
Table 1. Sequences of PNA and CPP-PNA Conjugates
Designation
CPP Alone or
Conjugate
Sequence of Peptide or CPP-PNA
Conjugates
P1 (D-Arg)8 RRRRRRRRG
P2 (D-Lys)4 KKKKG
Fluorescein-PNA Flk-(D-Arg)8-PNA
Flk-RRRRRRRRG-gcaatgtagacgtaa-
K-NH2
P1-PNA (D-Arg)8-PNA RRRRRRRRG-gcaatgtagacgtaa-K-NH2
P1-MM PNA (D-Arg)8-MM PNA RRRRRRRRG-gcaaggtagacttaa-K-NH2
P2-PNA (D-Lys)4-PNA KKKKG-gcaatgtagacgtaa-K-NH2
P2-MM PNA (D-Lys)4-MM PNA KKKKG-gcaaggtagacttaa-K-NH2
Sequences are shown in uppercase letters for peptides and in lowercase letters for PNA.
PNAs are written from their N to C termini, and the N terminus corresponds to the 50
end of a conventional oligonucleotide. The PNA sequence targets the epsilon of the
DHBV sequence (position 2573–2587). The replaced nucleotides in the mismatched
PNA are underlined. Flk, ε-ﬂuoresceinated lysine.45
www.moleculartherapy.organ antiviral effect following i.v. injection in ducklings. This is of
particular interest because to date, the in vivo route of delivery and
antisense efﬁcacy of CPP-PNAs has exclusively been investigated in
mice,34 which weigh less than 30 g. For comparison, the neonatal
Pekin ducklings used as a model in the present study grow extremely
fast, weighing about 50 g at the beginning of treatment and reaching
150 g by its end (day 6). Thus, we provide novel evidence that i.v. in-
jected CPP-PNA conjugates can be delivered into hepatocytes and
exhibit a biological effect in larger animals than mice.
One of the main objectives of this study was to investigate whether the
injection of CPP-PNA conjugates was able to inhibit hepadnaviral
replication. The target region of antisense PNA was the bulge (asym-
metric internal loop) and upper stem of the DHBV encapsidation
signal ε located at the pregenomic viral RNA. Because ε is essential
for hepadnavirus replication and RT of pregenomic RNA,35,36 it is
not surprising that the release of viral particles was markedly
decreased. Moreover, all intrahepatic viral DNA forms, including
the covalently closed circular DNA (cccDNA), were decreased
following in vivo treatment with CPP-PNA conjugates. However,
the 2-base mismatched PNA coupled to the same CPP (P1) and
used as speciﬁcity control exhibited an almost similar antiviral effect.
This was a rather unexpected ﬁnding because we have previously
demonstrated that the same double-mismatched PNA, tested in the
absence of CPP in a cell-free system for DHBV polymerase expres-
sion, had no effect on the RT reaction.20 Thus, an inhibitory effect
on viral replication of the CPP vehicle (D-Arg)8 alone, affecting the
speciﬁcity of CPP-PNA conjugates, was suspected. Indeed, it has
been shown that some natural CPPs, which are rich in basic amino
acids, exhibit different biologic activities, such as an antifungal or
antimicrobial effect.37 In addition, the antiviral activity of some
CPPs has been reported toward enveloped viruses such as HSV and
HIV38–40 and, more recently by us, for a CatLip displaying an inhib-
itory effect on hepadnaviral secretion.21,41 However, the contribution
of the antiviral activity of CPPs to the antisense potential of CPP-PNA
conjugates was not explored.To address this issue, we compared the in vitro antiviral activity of
anti-ε PNA conjugated to different CPPs using a PDH culture. Inter-
estingly, our in vitro results were consistent with and reinforced the
in vivo data because (D-Arg)8 P1-PNA conjugates as well as 2 nt
MM PNA conjugated to P1 and P1 alone inhibited DHBV replication
in PDHs. By contrast, the same PNA targeting ε, but coupled to
another CPP (D-Lys)4 (P2), inhibited DHBV replication in a
sequence-speciﬁc manner because neither P2-MM PNA conjugates
nor P2 alone exhibited signiﬁcant anti-DHBV activity. Collectively,
our results suggest that the choice of a CPP used as a vehicle for intra-
cellular delivery of PNAs may play an essential role in the ability of
CPP-PNA conjugates to speciﬁcally inhibit hepadnaviral replication.
Because some CPPs, such as (D-Arg)8, exhibit an inhibitory effect on
DHBV replication, this can have a major impact on antiviral activity
and speciﬁcity of CPP-PNA conjugates. In the absence of signiﬁcant
antiviral activity of CPP, a sequence-speciﬁc inhibition of DHBV
replication was observed for (D-Lys)4 conjugated to the same PNA.
A better understanding of the antiviral activities of different CPPs
is essential for their therapeutic application as transport vehicles for
PNA delivery, warranting further studies aiming at evaluating their
mechanisms of action. In this regard, in vitro studies with additional
controls to discriminate between peptide activity and PNA binding to
a target viral nucleic acid sequence will be of particular importance.
Taken together, we provide here the ﬁrst evidence that CPP-PNA
conjugates injected i.v. can enter hepatocytes and inhibit hepadnavi-
ral replication in vivo at a low dose, without observed toxicity, sug-
gesting the potential usefulness of this approach for hepatitis B ther-
apy. Importantly, our data strongly suggest that the difference in
antiviral activity of some CPPs, in the absence of their PNA cargo,
may play a key role in CPP-PNA conjugate speciﬁcity. Moreover,
the results presented here demonstrate that conjugation of anti-ε
PNA to (D-Lys)4 led to the inhibition of hepadnaviral replication,
without compromising sequence speciﬁcity. The anti-HBV potential
of such and similar CPP-PNAs needs to be further explored in asso-
ciation with new-generation NUCs, novel inhibitors targeting viral
morphogenesis and immune modulators in the context of innovative
therapeutic strategies aiming at achieving a functional cure for
chronic hepatitis B.
MATERIALS AND METHODS
Synthesis of PNA and CCP-PNA Conjugates
The PNAs were synthesized by Boc-solid phase chemistry as previ-
ously described,15,42 and sequences are summarized in Table 1.
Virus
A pool of viremic sera from ducklings infected with the cloned and
sequenced DHBV was used as an inoculum.43 This inoculum was
quantiﬁed into virus genome equivalents (vge) by quantitative dot-
blot hybridization, as described previously.22,23
Animals
3-day-old DHBV-free Pekin ducklings originating from a com-
mercial supplier were i.v. inoculated with a DHBV-positive serumMolecular Therapy: Nucleic Acids Vol. 9 December 2017 167
Molecular Therapy: Nucleic Acids(4  109 vge per duck), as previously described.22,24 Animal experi-
mentation was performed in accordance with the guidelines of animal
care and ethics of the National Veterinary School of Lyon (VetAgro
Sup, Marcy L’Etoile, France).
PDH Cultures
Fetal hepatocytes were isolated from Pekin duck embryos as previ-
ously described.43 DHBV infection was performed in serum-freeWil-
liam’s medium, 24 hr after plating by incubation of hepatocytes with a
pool of DHBV-positive duck serum (50 vge per cell). Hepatocytes
were seeded on collagen-coated 12-well plates (Biocoat, Becton Dick-
inson, Heidelberg, Germany) at a density of 1 106 cells per well, and
the growth medium was supplemented with 5% fetal calf serum and
changed daily. Antisense PNAs (2 mM ﬁnal) conjugated to CPPs or
CPPs alone (2 mM ﬁnal) were added to the culture medium daily
starting from 2 hr post-infection, as previously described.21 The
PDHs were treated during 6 days and lysed on day 7, followed by viral
replication analysis. Each experiment was repeated three to four
times. The cellular toxicity was analyzed by daily examination of cells
with a light microscope and cell toxicity test based on the neutral red
dye uptake, as described.44
Optimization of CPP-PNA Conjugate Delivery In Vivo
For the in vivo study of PNA distribution, two different delivery
routes were tested, i.e., the i.v. route via the occipital sinus and the
i.p. route. 1 mg/gbw/day of ﬂuorescein-labeled PNA coupled to
(D-Arg)8 CPP was injected via either the i.v. or i.p. route to two
groups of four ducklings. 48 hr after ﬂuorescein-PNA injection, all
animals were sacriﬁced and frozen liver, spleen, lung, and kidney sec-
tions were analyzed by ﬂuorescence microscopy (Leica, France,
DMLB 100), as previously described.23 The distribution of PNA
administrated by both routes was compared.
Therapeutic Protocol
DHBV-injected ducklings were randomly assigned to 3 groups of four
animals, which were either treated with CPP-PNA conjugates
(1 mg/gbw/day) or untreated. Ducklings received a daily i.v. injection
of CPP-PNA conjugates or CPP alone into the occipital sinus starting
2 hr after DHBV infection and daily during 6 consecutive days. Blood
samples were collected daily during the viremia follow up. The
toxicity was evaluated by daily follow up of animal weight. All animals
were sacriﬁced at the end of therapy (day 6 p.i.), and liver necropsy
samples were snap-frozen and stored at 80C for molecular
analysis.
Detection of Viral DNA
DHBV DNA was detected in duck serum or supernatant of PDH by
dot-blot hybridization by using a full-length 32P-labeled DHBV
probe, as described previously.24 Total liver DNA was obtained
from 0.2 g of frozen tissue homogenized in liquid nitrogen as
described.24 DNA was extracted from frozen necropsy liver samples
or PDH and 10 mg of the total DNA were subjected to electrophoresis
on 1% agarose gel, followed by Southern blot analysis and hybridiza-
tion with a 32P-labeled genomic DHBV probe as previously168 Molecular Therapy: Nucleic Acids Vol. 9 December 2017described.24,25 The EcoRI-linearized, cloned DHBV DNA was used
as an additional control. Viral DNA was quantiﬁed by PhosphorIm-
ager scanning using ImageQuant software (Molecular Dynamics).
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